Comparative Pharmacology
Head-to-head clinical analysis: ILOTYCIN GLUCEPTATE versus PEDIAMYCIN 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOTYCIN GLUCEPTATE versus PEDIAMYCIN 400.
ILOTYCIN GLUCEPTATE vs PEDIAMYCIN 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin gluceptate is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
Erythromycin gluceptate (Ilotycin Gluceptate) is administered intravenously at a dose of 250-500 mg every 6 hours for adults. Maximum daily dose: 4 g.
400 mg orally every 6 hours for 10 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in adults with normal renal function; may be prolonged in hepatic impairment (up to 5-6 hours).
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Primarily hepatic metabolism and biliary excretion; about 10-15% excreted unchanged in urine; some fecal elimination due to biliary excretion.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic